We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biotech Acquisition Company | NASDAQ:BIOT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.15 | 10.13 | 10.20 | 0 | 00:00:00 |
Filed by Biotech Acquisition Company
pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended,
under the Securities Exchange Act of 1934, as amended
Subject Company: Biotech Acquisition Company
Commission File No.: 001-39935
Date: May 19, 2022
| a. | Social Media |
On May 19, 2022, Blade shared the following on its LinkedIn page:
The American Thoracic Society 2022 International Conference is a wrap! Thank you to everyone who took the time to interact with the Blade team at our poster presentations and exhibit booth. After hearing from so many people throughout the meeting, we could not be more excited to work with the respiratory community to bring life-changing treatments to patients.
And #ICYMI, check out our news from #ATS2022 by visiting https://lnkd.in/gbPJtcjQ
Hashtags: Wendye Robbins American Thoracic Society #tbt #ipf #fibrosis #clinicalresearch #clinicaldevelopment
IMPORTANT LEGAL INFORMATION
The foregoing information and statements contained in this Rule 425 filing are qualified in their entirety by the disclaimers set forth on the Form 8-K filed by Biotech Acquisition Company with the SEC on November 8, 2021.
1 Year Biotech Acquisition Chart |
1 Month Biotech Acquisition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
